StreetAlpha.app
Home › Stocks › PDSB

PDS Biotechnology Corp (PDSB)

Healthcare
$0.78
▼ −3.70%
LAST CLOSE · NOV 20

PDS Biotechnology develops immunotherapies that aim to treat cancer and to prevent infectious diseases. It last closed at $0.78 on Nov 20, down 3.70% on the day. The next earnings report for PDSB is expected around Mon, Mar 29, 2027. For the quarter ended Sep 2026, PDSB reported EPS of -$0.11. Over its last 8 reports the stock moved an average of 6.9% the session after earnings.

AI Auto Pilots
Is PDSB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PDSB.

Key Stats

Last 12 months
Results
Net income
−$32.3M
EPS (diluted)
−$0.54
Valuation
Market cap
$81.6M
105.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$15.2M
At Sep 30
Shareholder equity
$13.5M
Shares outstanding
105.0M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$16.9M−$16.9MFY2021FY2022: −$40.9M−$40.9MFY2022FY2023: −$42.9M−$42.9MFY2023FY2024: −$37.6M−$37.6MFY2024FY2025: −$34.5M−$34.5MFY2025

From PDSB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · Time not announced
Reported EPS
-$0.11
Quarter ended Sep 2026
Year ago EPS
-$0.19
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.21Dec '24Mar 2025: -$0.21Mar '25Jun 2025: -$0.21Jun '25Sep 2025: -$0.19Sep '25Dec 2025: -$0.14Dec '25Mar 2026: -$0.13Mar '26Jun 2026: -$0.18Jun '26Sep 2026: -$0.11Sep '26Latest -$0.11
Revenue by quarter
Not enough quarters on file yet.
How PDSB moved after its last 8 reports
Average move the session after a report ±6.9%
Nov 13, 2026Time not announced−11.0%
Aug 13, 2026Time not announced−3.6%
May 13, 2026Time not announced+20.9%
Mar 30, 2026Time not announced−0.9%
Nov 12, 2025Time not announced−9.1%
Aug 13, 2025Time not announced−5.7%
May 14, 2025Time not announced+3.1%
Mar 27, 2025Time not announced+0.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PDSBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PDSB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PDSB

Technical Analysis

PDSB · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 45% below its 20 day and 34% below its 50 day average. It is 8% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot S1 at $0.75, and the nearest resistance the 100 day average at $0.78.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 20.6%/day
Key levels
$1.7952 week high+129.5%
$1.1320 day average+44.9%
$1.0450 day average+33.3%
$0.84200 day average+7.7%
$0.82Pivot R1+5.1%
$0.80Pivot+2.6%
$0.80Swing high (Aug 10)+2.6%
$0.78100 day average+0.0%
$0.78Last close
$0.75Pivot S1−3.8%
$0.75Swing low (Nov 13)−3.8%
$0.2052 week low−74.4%
Indicators
RSI (14)38.12Weak, oversold below 30Neutral
MACD-0.08Below its signal lineBearish
Stochastic5.0Near the bottom of its rangeOversold
ADX (14)28.2Trending down
Williams %R-96.5Oversold below −80, overbought above −20Oversold
CCI (20)-103.6Oversold below −100, overbought above 100Oversold
Rate of change−36.8%Change over 10 sessionsBearish
ATR (14)$0.16Typical daily range, 20.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Below
What happened before, for PDSB

What happened before

See how PDSB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PDSB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PDSB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PDSBHow many large options trades hit PDSB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PDSB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲32 buying vs 18 selling
  • ▲Held by funds +4.7 pts
  • ▲Funds holding +10
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6252+19.2%
In funds' top 1000–
Held by funds12.1%7.3%+4.7 pts
New / increased18 / 1414 / 13+18.5%
Reduced / sold out12 / 67 / 4+63.6%
Put/call ratio0.290.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PDSB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PDSB Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Feb 28, 2025Stephen C. GloverDirectorBuy15,061$1.66$25K
Feb 28, 2025Gregory Gene FreitagDirectorBuy15,060$1.66$25K
Every insider buy and sale for PDSB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PDSB insider trades →

From SEC Form 4 filings by PDSB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PDSB is in one of them and how their past PDSB trades turned out.

PDSB in the AI portfolios
Loading…

PDSB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PDSB in an article yet. Here's the latest on the wider market.

PDSB in the news

About PDS Biotechnology

PDS Biotechnology is a clinical stage immunotherapy company based in Princeton, New Jersey. It is developing cancer treatments built on its Versamune platform, including a combination with an interleukin 12 antibody drug conjugate, and an Infectimune T cell activator for preventive vaccines against infectious agents. The Versamune platform is a lipid nanoparticle designed to stimulate the immune system's killer and helper T cells. Its investigational products are aimed at patients with cancer and at preventive vaccines for infectious diseases.

Headquarters
Princeton, NJ